Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $100 Million At-The-Market Offering Facility
Press Release – New York, NY – April 14, 2022 – Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: “RLMD”), a late-stage biotechnology company, in a $100 million At-The-Market offering facility (“ATM”).
The shares were registered on RLMD’s Registration Statement on Form S-3 (File No. 333-264189) filed with the Securities and Exchange Commission on April 7, 2022.
Jefferies LLC acted as agent for the ATM.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia and Barrett DiPaolo and associate Matt Siracusa.
- Litigation Paralegal - November 28, 2022
- Sichenzia Ross Ference to Sponsor Gravitas Securities 6th Annual Growth Conference - November 22, 2022
- Memorandum RE: Pay v. Performance Disclosure Rules - November 22, 2022